Nuwellis (NASDAQ:NUWE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Nuwellis (NASDAQ:NUWE) to a hold rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Nuwellis in a report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Nuwellis presently has an average rating of “Sell”.

Nuwellis Trading Up 5.3%

Shares of NUWE stock opened at $3.00 on Friday. The business’s 50-day moving average price is $13.38 and its 200-day moving average price is $42.98. Nuwellis has a 12 month low of $2.73 and a 12 month high of $555.45. The firm has a market capitalization of $240,000.00, a price-to-earnings ratio of -0.00 and a beta of 0.29.

Nuwellis (NASDAQ:NUWE) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($73.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($35.00) by ($38.15). The firm had revenue of $2.40 million during the quarter, compared to analyst estimates of $2.09 million. Nuwellis had a negative net margin of 214.90% and a negative return on equity of 32,351.83%.

Institutional Trading of Nuwellis

An institutional investor recently raised its stake in Nuwellis stock. Sabby Management LLC increased its stake in Nuwellis, Inc. (NASDAQ:NUWE) by 149.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 89,685 shares of the company’s stock after acquiring an additional 53,791 shares during the quarter. Nuwellis accounts for approximately 0.2% of Sabby Management LLC’s portfolio, making the stock its 18th largest position. Sabby Management LLC owned approximately 4.80% of Nuwellis worth $156,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 3.13% of the company’s stock.

About Nuwellis

Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid?overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low?shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.